Literature DB >> 21410286

Quantitative proteomic analysis of dystrophic dog muscle.

Laetitia Guevel1, Jessie R Lavoie, Carolina Perez-Iratxeta, Karl Rouger, Laurence Dubreil, Marie Feron, Sophie Talon, Marjorie Brand, Lynn A Megeney.   

Abstract

Duchenne muscular dystrophy (DMD) is caused by null mutations in the dystrophin gene, leading to progressive and unrelenting muscle loss. Although the genetic basis of DMD is well resolved, the cellular mechanisms associated with the physiopathology remain largely unknown. Increasing evidence suggests that secondary mechanisms, as the alteration of key signaling pathways, may play an important role. In order to identify reliable biomarkers and potential therapeutic targets, and taking advantage of the clinically relevant Golden Retriever Muscular Dystrophy (GRMD) dog model, a proteomic study was performed. Isotope-coded affinity tag (ICAT) profiling was used to compile quantitative changes in protein expression profiles of the vastus lateralis muscles of 4-month old GRMD vs healthy dogs. Interestingly, the set of under-expressed proteins detected appeared primarily composed of metabolic proteins, many of which have been shown to be regulated by the transcriptional peroxisome proliferator-activated receptor-gamma co-activator 1 alpha (PGC-1α). Subsequently, we were able to showed that PGC1-α expression is dramatically reduced in GRMD compared to healthy muscle. Collectively, these results provide novel insights into the molecular pathology of the clinically relevant animal model of DMD, and indicate that defective energy metabolism is a central hallmark of the disease in the canine model.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21410286     DOI: 10.1021/pr2001385

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  28 in total

1.  Proteomic profiling of the dystrophin complex and membrane fraction from dystrophic mdx muscle reveals decreases in the cytolinker desmoglein and increases in the extracellular matrix stabilizers biglycan and fibronectin.

Authors:  Sandra Murphy; Heinrich Brinkmeier; Mirjam Krautwald; Michael Henry; Paula Meleady; Kay Ohlendieck
Journal:  J Muscle Res Cell Motil       Date:  2017-08-12       Impact factor: 2.698

Review 2.  ROS and RNS signaling in skeletal muscle: critical signals and therapeutic targets.

Authors:  Luke P Michaelson; Colleen Iler; Christopher W Ward
Journal:  Annu Rev Nurs Res       Date:  2013

Review 3.  Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials.

Authors:  Joe N Kornegay; Christopher F Spurney; Peter P Nghiem; Candice L Brinkmeyer-Langford; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  ILAR J       Date:  2014

4.  Quantitative proteomic analysis reveals metabolic alterations, calcium dysregulation, and increased expression of extracellular matrix proteins in laminin α2 chain-deficient muscle.

Authors:  Bruno Menezes de Oliveira; Cintia Y Matsumura; Cibely C Fontes-Oliveira; Kinga I Gawlik; Helena Acosta; Patrik Wernhoff; Madeleine Durbeej
Journal:  Mol Cell Proteomics       Date:  2014-07-03       Impact factor: 5.911

5.  Sparing of the dystrophin-deficient cranial sartorius muscle is associated with classical and novel hypertrophy pathways in GRMD dogs.

Authors:  Peter P Nghiem; Eric P Hoffman; Priya Mittal; Kristy J Brown; Scott J Schatzberg; Svetlana Ghimbovschi; Zuyi Wang; Joe N Kornegay
Journal:  Am J Pathol       Date:  2013-11       Impact factor: 4.307

6.  Novel approach to meta-analysis of microarray datasets reveals muscle remodeling-related drug targets and biomarkers in Duchenne muscular dystrophy.

Authors:  Ekaterina Kotelnikova; Maria A Shkrob; Mikhail A Pyatnitskiy; Alessandra Ferlini; Nikolai Daraselia
Journal:  PLoS Comput Biol       Date:  2012-02-02       Impact factor: 4.475

7.  Simultaneous Pathoproteomic Evaluation of the Dystrophin-Glycoprotein Complex and Secondary Changes in the mdx-4cv Mouse Model of Duchenne Muscular Dystrophy.

Authors:  Sandra Murphy; Michael Henry; Paula Meleady; Margit Zweyer; Rustam R Mundegar; Dieter Swandulla; Kay Ohlendieck
Journal:  Biology (Basel)       Date:  2015-06-10

8.  Exploration of lipid metabolism in relation with plasma membrane properties of Duchenne muscular dystrophy cells: influence of L-carnitine.

Authors:  Françoise Le Borgne; Stéphane Guyot; Morgan Logerot; Laurent Beney; Patrick Gervais; Jean Demarquoy
Journal:  PLoS One       Date:  2012-11-27       Impact factor: 3.240

9.  Metabolic remodeling agents show beneficial effects in the dystrophin-deficient mdx mouse model.

Authors:  Vanessa E Jahnke; Jack H Van Der Meulen; Helen K Johnston; Svetlana Ghimbovschi; Terrence Partridge; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  Skelet Muscle       Date:  2012-08-21       Impact factor: 4.912

10.  Profiling of age-related changes in the tibialis anterior muscle proteome of the mdx mouse model of dystrophinopathy.

Authors:  Steven Carberry; Margit Zweyer; Dieter Swandulla; Kay Ohlendieck
Journal:  J Biomed Biotechnol       Date:  2012-10-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.